Chad (ChangDeok) Ji

SamOh Pharmaceutical, built over 20 years on BD-driven license-in strategies, has introduced numerous ultra-rare and specialty care products to the Korean market, including Genzyme’s lysosomal storage disorder (LSD) therapies and Recordati Rare Disease’s PKU and NAGs. The company is preparing to launch Biomarin’s MPS portfolio (MPS 4A, MPS 6) and Voxzogo, the world’s first treatment for achondroplasia, a first-in-class therapy addressing a condition with no previous treatment options and significant unmet medical need. Voxzogo represents a transformative opportunity for patients and the specialty care market in Korea. • Established the company’s first specialty care and rare disease-focused commercial organization • Led new product launches across rare and specialty care areas, including strategic preparation for Voxzogo’s market introduction for achondroplasia patients. • Developed and implemented corporate culture, operational systems, and cross-functional team frameworks to support sustainable growth • Embedded a patient-centric approach into organizational processes and strategies • Directly responsible for Business Development (BD), identifying and licensing new specialty care and rare disease opportunities, with plans to further expand the BD portfolio

I founded ZBRA Pharma Consulting based on my extensive experience in the Korean pharmaceutical industry, particularly in rare and specialty care, to help global biopharma companies enter and expand in Korea and Asia. We have successfully delivered projects in strategy, commercialization, and market establishment, supporting clients from GTM design to execution. 📌 Pharmaceutical & Specialty Care Consulting – Strategic Advisory 1. Pharma Strategy & Commercialization Project • Successfully conducted due diligence and market entry assessments for neurodegenerative and specialty care therapies in South Korea • Delivered salesforce KPI benchmarking & optimization, improving commercial performance • Advised on Early Access Programs (EAP) and Named Patient Programs (NPP), enabling earlier access to innovative therapies • Designed and executed GTM strategies and commercialization plans leading to successful launches 2. Market Entry & Business Establishment Strategy Project • Provided market insights across rare and specialty care areas in Korea & Taiwan • Supported multinational companies in establishing local entities and operational models • Developed patient support programs that improved access and adherence • Guided diagnostic and biomarker applications for precision medicine in specialty care • Conducted competitive landscape analyses for strategic positioning in Korea 3. Focused Therapy Areas Market Insight Project • Lysosomal Storage Disorder (LSD) management strategies • Fabry disease market research across Asia • hATTR-CM and cardiovascular specialty care market evaluations • Hemophilia drug launch strategies in South Korea • HAE therapy commercialization and market access in Asia 📌 Publications & Article Writing 1. Pharmaceutical and Specialty Care Market in Asia 2. Overview of Korea’s Specialty Care Market 3. Key Considerations for Establishing a Specialty Care Business in Korea 4. Promising Specialty Care Segments in Korea (3-part series)

Antler Korea – Cohort 6 (Acceleration Program) Participated in Antler Korea’s Cohort 6, an acceleration program designed to build startups by identifying co-founders, developing business ideas, and securing seed investment. Within the healthcare track, I worked on several concepts including: • SaaS solutions leveraging patient support programs in the pharmaceutical industry to generate real-world evidence • A patient-centric data platform returning ownership of genetic data to patients Through this experience, I gained significant insights into identifying and validating real market problems beyond assumptions, and translating them into viable business opportunities. Collaborating with co-founders from diverse backgrounds, nationalities, experiences, and age groups further enhanced my ability to communicate effectively and lead in highly dynamic, cross-functional environments.

Accelerate business growth through integrated rare specialty diseases and new product launch • Demonstrated a consistent trajectory of revenue increase achieving track record growth and fostered a resilient organizational culture and retained key talent during company integrations and COVID-19 pandemic. • Championed key company-wide projects such as new digital workflow for transformative growth, leading a corporate culture . • Distinguished in the global arena for launch excellence, I spearheaded the creation of a new market for Hereditary Angioedema(HAE) treatments in the Allergy and Dermatology sectors. • Instrumental in introducing a second line(2L) Cytomegalovirus(CMV) Standard of Care by developing an Early Access Program(EAP) scheme.

• Orchestrated a strategic organizational restructuring to enhance sustainable growth and market leadership. • Revolutionized the diagnostic landscape by developing diagnostic collaboration model with Centogene, Revvity and AI tech startups like 3Billion and Inocras. • Established a benchmark in patient care with self-infusion at home for LSD patients and successfully broaden reimbursement policies in HAE market. • Effectively prioritized and managed the local asset portfolio and conducted comprehensive business feasibility assessments in Metachromatic Leukodystrophy, Dravet/Lenox-Gastaut Syndrome, Hyperthyroidism, Marfan and Cushing Syndrome, etc. # Areas: HAE, CMV, Fabry, Gaucher, MLD, Dravet/Lennox Gastaut, Hypothyroidism disease in Cardio, Nepro, Neuro, Ped-Gen, Hema, Allergy, Pulmo, Derma, GI, Endo, etc.

Specialized in orchestrating business takebacks, establishing new business, and spearheading their commercialization. • Market Penetration: Achieved the fastest-growing business in the APAC region with a 25% market share by implementing a successful patient switch-in strategy and deep market penetration. • Business Takebacks: Proficiently managed global distributor business models, leading the business takeback process with strategic planning and execution, and established a new business unit with rapid hiring and team building. • Product Launch: Demonstrated determined leadership by securing Pricing & Reimbursement (P&R) approval for key Hereditary Angioedema (HAE) products, marking a significant milestone after three rigorous trial phases.

Committed to scaling up business models and enhancing systemic processes for commercial excellence. • Revenue Growth: Successfully doubled revenue from $12M to $25M, achieving an 82% market share with a 44% CAGR through strategic business scaling and market dominance. • Collaborative Culture: Spearheaded the development of a supportive and integrated work environment post-merger, ensuring seamless integration of sales, marketing, and medical teams. • Strategic Expansion: Expanded reimbursement guidelines and developed innovative strategies for patient identification, such as establishing a third-party laboratory infrastructure for extensive screening and enhancing test reliability.

Dedicated to nurturing blockbuster products and ensuring sustainable growth, not only through successful new product launches but also by extending the Product Life Cycle. • Sales Growth: Grew sales from $18M to $57M, achieving a 33% CAGR and maintaining a 70% market share amidst generic competition by nurturing blockbuster products and extending their Product Life Cycle. • Product Life Cycle: Successfully negotiated and secured a self-development line extension for the Sustained-Release Tablet and strategically expanded into new strengths, enhancing the product's market presence. • Sales Performance: Recognized three times as a top sales performer, consistently surpassing annual targets by over 180%, and effectively communicated with over 1,000 internal and external stakeholders to ensure strong relationships and efficient operations. # Areas: Hypertension, Angina, Heart failure, hyperlipidemia in Cardio, Nepro, Neuro, Endo, etc.